|
| Publications |
Publications in peer-reviewed journals21. J.G. van den Boorn, D. Konijnenberg, E.P.M. Tjin, D.I. Picavet, N.J. Meeuwenoord, D.V. Filippov, J.P.W. van der Veen, J.D. Bos, C.J.M. Melief, R.M. Luiten. Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG PloS ONE 2010, published 13 May 2010, [download article] 20. N.A. van Geel, I.G. Mollet, S. De Schepper, E.P.M. Tjin, K. Vermaelen, R.A. Clark, T.S. Kupper, R.M. Luiten, J. Lambert. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 2010 Apr 1. [Epub ahead of print]. 19. J.G. van den Boorn, D. Konijnenberg, T.A.M. Dellemijn, J.P. W. van der Veen, J.D. Bos, C.J.M. Melief, F.A. Vyth-Dreese and R.M. Luiten. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol, 2009, 129: 2220–2232. 18. K.U. Schallreuter, P. Bahadoran, M. Picardo, A. Slominski, Y.E. Elassiuty, E.H. Kemp, C. Giachino, J.B. Liu, R.M. Luiten, T. Lambe, I.C. Le Poole, I. Dammak, H. Onay, M.A. Zmijewski, M.L. Dell'Anna, M.P. Zeegers, R.J. Cornall, R. Paus, J.P. Ortonne and W. Westerhof. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Controversies in Experimental Dermatology, Experimental Dermatology 2008, 17(2): 139-140. 17. RM Luiten. Vitiligo bij melanoom: een gunstig teken. Nederlands Tijdschrift voor Oncologie 2006, jaargang 3, nr 6:224-230 [in pdf]. 16. E.A. Reits, J.W. Hodge, C.A. Herberts, M. Chakraborty, E.K. Wansley, K. Camphausen, J. Schlom, R.M. Luiten, A de Ru, TA Groothuis, A Griekspoor, E Mesman, F Verreck, H Spits, P van Veelen, JJ Neefjes. Radiation modulates the peptide repertoire of MHC class I molecules and induces successful anti- tumor immunotherapy. J Exp Med, 2006; 203(5):1259-71. 15. J.G. van den Boorn, I.C. LePoole, R.M. Luiten. T cell avidity and tuning: the flexible connection between tolerance and autoimmunity. International Reviews of Immunology 2006;25(3-4):235-58. 14. K. Oyarbide-Valencia, J.G. van den Boorn, C. Denman, J. Carlson, C. Hernandez, M.I. Nishimura, P.K. Das, R.M. Luiten and I.C. Le Poole. Therapeutic implications of autoimmune vitiligo T cells. Autoimmunity Reviews 2006; 5(7):486-92. 13. RM Luiten, E.W.M. Kueter, W. Mooi, M.P.W. Gallee, E.M. Rankin, W.R. Gerritsen, S.M. Clift, W.J. Nooijen, P.Weder, W.F. van de Kasteele, J. Sein, P.C.M. van den Berk, O.E. Nieweg, A.M. Berns, H. Sptis and G.C. de Gast. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Journal of Clinical Oncology. 2005; 23(35), [pdf] Featured as editorial by William E. Carson [in pdf] 12. N.C.V. Verra, A. Jorritsma, K. Weijer, J.J. Ruizendaal, A. Voordouw, P. Weder, E. Hooijberg, T.N.M. Schumacher, J.B.A.G. Haanen, H. Spits and R.M. Luiten. hTERT-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Research. 2004, 64:2153-2161. [pdf]
10. RM Luiten, J Pène, H Yssel and H Spits. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T cell clones and confers resistance to oxidative stress-induced apoptosis Blood. 2003; 101(11): 4512-9. [pdf] 9. Luiten RM, Demotte N, Tine J, van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens. 2000 Jul;56(1):77-81. [PubMed] 8. Luiten R, van der Bruggen P.A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens. 2000; 55(2):149-52. [PubMed] 7. Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999; 163(5):2928-36. [pdf] 6. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999; 189(5):767-78. [pdf] 5. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer. 1996; 74(5):735-44. [PubMed] 4. Luiten RM, Fleuren GJ, Warnaar SO, Litvinov SV. Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma associated antigen. Lab Invest. 1996; 74(2):467-75. [PubMed] 3. Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR Jr, Coney LR. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J Immunother. 1997; 20(6):496-504. [PubMed] 2. Luiten RM, Warnaar SO, Schuurman J, Pasmans SG, Latour S, Daeron M, Fleuren GJ, Litvinov SV. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells. Hum Antibodies. 1997;8(4):169-80. [PubMed] 1. de Koster HS, Kenter MJ, D'Amaro J, Luiten RM, Schroeijers WE, Giphart MJ, Termijtelen A. Positive correlation between oligonucleotide typing and T-cell recognition of HLA-DP molecules. Immunogenetics. 1991;34(1):12-22. [PubMed] Book ChaptersJan D. Bos and Rosalie M. Luiten Caroline Le Poole and Rosalie M. Luiten Patents3. Chaux, R.M. Luiten, N. Demotte, M.T. Duffour, C. Lurquin, C. Traversari, V. Stroobant, G.R. Cornelis, T. Boon-Falleur, P. van der Bruggen, E Schultz and G. Warnier. Tumor antigens and CTL clones isolated by a novel procedure 2. R.M. Luiten, T. Boon-Falleur, P. van der Bruggen, V. Stroobant, N. Demotte and E. Schultz. MAGE antigenic peptides, which bind HLA-B35 and B44 1. P. Chaux, T. Boon-Falleur, R.M. Luiten, C. Heirman, V. Stroobant, J. Corthals, K. Thielemans, P. van der Bruggen. MAGE-3 peptides presented by HLA Class II molecules. Publications about my research6: A press release about the disseratation of my phd-student Jasper van den Boorn drew a lot of media attention. It was published in De Telegraaf (the biggest newspaper in the Netherlands), but also on a lot of newswebsites, like Nu.nl, Metro, Medicalfacts.nl, Gezondheidsnet.nl, Artsennet.nl, Zorg.nieuwslog, Folia.nl, Amsterdam Biomed and Drimble weblog. It also led to an interview on BNR Newsradio. 5. E. Gerritsma "De werkplek", Status, May 2007 (interview with R.M. Luiten) 4. J. Ekkelboom "Therapie met witte vlekken. Een kleurloos wapen tegen huidkanker", AMC magazine 3, 2006; 20-21. 3. W. Carson. "Getting melanoma cells to stimulate with frequency" Editorial, J. Clin. Oncol. 2005; 23(35): 8929-8931. [in pdf] 2. I. van Elsakker. "Witte vlekken tegen huidkanker", AMC magazine 2005; 5:30. 1. W. van Strien. "Witte vlekken wijzen de weg", Cicero 2004; 13:18-19 (Magazine of the Leiden University Medical Center, The Netherlands). In addition, more than 5 press releases were published by the University of Leiden, Amsterdam and The Netherlands Organization of Scientific Research to announce the candidate as Laureate of the NWO-VIDI personal fellowship. Other publications8. "Meer succes met therapie voor vitiligo", Newsletter January 2006 of the LVVP, The Dutch Society of Vitiligo Patients 7. "Communicating European Research: the importance of explaining science to the public", Report of the EC conference CER2005 (Brussels, November 2005 ), MCFA website 6. "The Europe of Knowledge: a blueprint for competitive research in Europe", Report of EC conference Europe of Knowlegde 2020 (Liège, April 2004), MCFA website. 5. "Europe's hope: the strategy of togetherness", Report of the Thursday meeting of the EESC (Brussels, January 2006), MCFA website 4. MCFA Welcome Document for the Belgian MCFA Group, MCFA website 3. Minutes of the MCFA First National Co-ordinators meeting (London, June 1999). 2. Meeting of the Dutch national group. 1. Minutes of the first Belgian group meeting. Rosalie Luiten has held more than 20 oral and poster presentations on the subject of cancer research, immunotherapy and gene therapy at international conferences, such as the Keystone symposia, Cancer Research Institute symposia and the European Society of Gene Therapy. She published the abstracts of these presentations in conference proceedings.
Share | . Ontwerp en realisatie: Nico van Dijk Media
|
11. A Röth, H Yssel, J Pène, EA Chavez, M Schertzer, PM Lansdorp, H Spits and RM Luiten. Telomerase levels control the lifespan of human T lymphocytes. Blood, 2003; 102(3): 849-57. [
Top